Zacks CommentaryNOV 42 min read$HRTX

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Original reporting

Zacks Commentary · Zacks Equity Research

Published Nov 4, 2025, 2:30 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Nov 5, 2025, 12:02 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Decision brief

The 30-second read

$HRTXNeutralLow

Why it matters

The earnings report aligns with analyst expectations, suggesting no immediate revaluation. Investors should consider broader industry trends and company-specific news for a comprehensive view.

Market read

While the earnings are in line with expectations, the impact on stock price is expected to be minimal, given the neutral surprise factor.

What to watch

Potential upcoming pipeline developments or regulatory decisions could influence future performance beyond current earnings.

Timing: short-term (next few days)

Background

Heron Therapeutics is a biotech company focusing on innovative therapies. The Q3 2025 earnings are a key indicator of its current financial health.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HRTXNeutralMedium confidence

Context

Heron Therapeutics Q3 2025 earnings report and comparison with Wall Street estimates.

Expected impact

Limited immediate price movement; potential for slight volatility depending on investor interpretation.

Evidence & confidence

The earnings figures are in line with expectations, suggesting no significant surprise. Market reactions are likely to be subdued, but minor volatility could occur based on investor sentiment.

Market effects

Sector

The pharmaceutical/biotech sector may experience minimal movement, as Heron Therapeutics' results are in line with expectations.

Regional

Limited regional impact; primarily affects investors and stakeholders in the US market.

Global

Low; the company's performance is unlikely to influence global markets significantly.

Counterpoint

What could challenge this read

Some investors might interpret the results as a sign of underlying stability, potentially supporting a cautious bullish stance.

Key entities

Company
Heron Therapeutics
A biotechnology company specializing in innovative therapies.
Analyst Group
Wall Street analysts
Financial analysts providing earnings estimates and market forecasts.

Read at source ← All news

AUG 29

$FULCMed

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.

stocktwits.com2 min

AUG 17

$HRTXMedAI 8/10

Heron (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics (HRTX) reported Q2 2026 net revenue of $37.7M, up from $34.7M in Q1 but below expectations. CINVANTI was $21.8M, ZYNRELEF $11.1M (+35% YoY), and APONVIE $4.2M (+74% YoY). After a June patent ruling, the company amended its Hercules credit facility, resetting covenants through 2027 and reducing principal. It withdrew full-year 2026 guidance.

yahoo.com7 min

AUG 10

$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

yahoo.com6 min

AUG 10

$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-year - Amended credit facility with Hercules

SEC EDGAR 8-K6 min

SEP 8

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min